Donor Testing and Risk: Current Prevalence, Incidence, and Residual Risk of Transfusion-Transmissible Agents in US Allogeneic Donations

Transfusion Medicine Reviews

Volumn 26, Issue 2, 2012, Pages 119-128

  Zou, Shimian ^a,b   Stramer, Susan L ^a,b   Dodd, Roger Y ^a,b  

^a HOLLAND LABORATORY   (United States)

^b AMERICAN RED CROSS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN;

ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CHAGAS DISEASE; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; GROUPS BY AGE; HEALTH EDUCATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; INCIDENCE; INFECTION PREVENTION; PREVALENCE; RISK FACTOR; TREPONEMA PALLIDUM; TREPONEMATOSIS; TRYPANOSOMA CRUZI; UNITED STATES; WEST NILE FLAVIVIRUS;

ANTIBODIES, BACTERIAL; ANTIBODIES, PROTOZOAN; ANTIBODIES, VIRAL; BLOOD DONORS; BLOOD SAFETY; CHAGAS DISEASE; HUMANS; INCIDENCE; POPULATION SURVEILLANCE; PREVALENCE; RED CROSS; RISK; SYPHILIS; TREPONEMA PALLIDUM; TRYPANOSOMA CRUZI; UNITED STATES; VIRUS DISEASES;

EID: 84858297990     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2011.07.007     Document Type: Article

References (63)

1. Dodd R.Y., Notari E.P., Stramer S.L. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002, 42:975-979.
2. Zou S., Musavi F., Notari E. Changing age distribution of the U.S. blood donor population-more young donors recruited and retained but the overall ageing trend continued. Vox Sang 2010, 99(Suppl. 1):165. (Abstract).
3. Eder A.F., Hillyer C.D., Dy B.A., Notari E.P., Benjamin R.J. Adverse reactions to allogeneic whole blood donation by 16- and 17-year-olds. JAMA 2008, 299:2279-2286.
4. Notari E.P., Zou S., Fang C.T., Eder A.F., Benjamin R.J., Dodd R.Y. Age related donor return patterns among first time blood donors in the United States. Transfusion 2009, 49:2229-2236.
5. American Red Cross. Red Cross Lists Requirements for Young Blood Donors. http://www.redcross.org/portal/site/en/menuitem.1a019a978f421296e81ec89e43181aa0/?vgnextoid=4e5fb1df14574210VgnVCM10000089f0870aRCRD.
6. Stramer S.L., Glynn S.A., Kleinman S.H., Strong D.M., Caglioti S., Wright D.J., et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004, 251:760-768. for the National Heart, Lung, and Blood Institute Nucleic Acid Test Study Group.
7. Stramer S.L., Foster G.A., Dodd R.Y. Effectiveness of human T-lymphotropic virus (HTLV) recipient tracing (lookback) and the current HTLV-I and -II confirmatory algorithm, 1999 to 2004. Transfusion 2006, 46:703-707.
8. Stramer S.L., Notari E.P., Zou S., Krysztof D.E., Brodsky J.P., Tegtmeier G.E., et al. HTLV antibody screening of blood donors: rates of false positive results and evaluation of a potential donor re-entry algorithm. Transfusion 2011, 51:692-701.
9. Zou S., Stramer S.L., Notari E.P., Kuhns M.C., Krysztof D., Musavi F., et al. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009, 49:1609-1620.
10. Zou S., Notari E.P., Fang C.T., Stramer S.L., Dodd R.Y. Current value of serologic test for syphilis as a surrogate marker for bloodborne viral infections among blood donors in the United States. Transfusion 2009, 49:655-661.
11. Zou S., Dorsey K.A., Notari E.P., Foster G., Krysztof D., Musavi F., et al. Prevalence, incidence and residual risk of HIV and HCV infections among US blood donors since the introduction of nucleic acid testing. Transfusion 2010, 50:1495-1504.
12. Zou S., Musavi F., Notari E.P., Stramer S.L., Dodd R.Y. Prevalence, incidence and residual risk of major blood borne infections among apheresis collections to the American Red Cross Blood Services, 2004-2008. Transfusion 2010, 50:1487-1494.
13. Stramer S.L., Custer B., Busch M.P., Dodd R.Y. Strategies for testing blood donors for West Nile virus. Transfusion 2006, 46:2036-2037.
14. Centers for Disease Control and Prevention (CDC) Blood donor screening for Chagas disease-United States, 2006-2007. MMWR 2007, 56:141-143.
15. Wu Y., Zou S., Cable R., Dorsey K., Tang Y., Hapip C.A., et al. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Transfusion 2010, 50:776-786.
16. Korelitz J.J., Busch M.P., Kleinman S.H., Williams A.E., Gilcher R.O., Ownby H.E., for the National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study, et al. A method for estimating hepatitis B virus incidence rates in volunteer blood donors. Transfusion 1997, 37:634-640.
17. Petersen L.R., Satten G.A., Dodd R.Y., Busch M., Kleinman S., Grindon A., et al. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. Transfusion 1994, 34:283-289. the HIV Seroconversion Study Group.
18. Schreiber G.B., Busch M.P., Kleinman S.H., Korelitz J.J. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996, 334:1685-1690.
19. Kleinman S., Busch M.P., Korelitz J.J., Schreiber G.B. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev 1997, 11:155-172.
20. Busch M.P., Glynn S.A., Stramer S.L., Strong D.M., Caglioti S., Wright D.J., et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005, 45:254-264. NHLBI-REDS NAT Study Group.
21. Kleinman S.H., Busch M.P. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006, 35(Suppl 1):S34-S40.
22. Manns A., Wilks R.J., Murphy E.L., Haynes G., Figueroa J.P., Barnett M., et al. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 1992, 51:886-891.
23. Orton S.L., Liu H., Dodd R.Y., Williams A.E. Prevalence of circulating Treponema pallidum DNA and RNA in blood donors with confirmed-positive syphilis tests. Transfusion 2002, 42:94-99. ARCNET Epidemiology Group.
24. Katz L.M. A test that won't die: the serologic test for syphilis. Transfusion 2009, 49:617-619.
25. Dow B.C., Franklin I.M., Munro H., Gunson R. Syphilis nucleic acid testing: usefulness in syphilis confirmation?. Transfusion 2010, 50:737-739.
26. O'Brien S.F., Yi Q.L., Fan W., Scalia V., Kleinman S.H., Vamvakas E.C. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007, 47:316-325.
27. Pealer L.N., Marfin A.A., Petersen L.R., Lanciotti R.S., Page P.L., Stramer S.L., et al. West Nile Virus Transmission Investigation Team. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003, 349:1236-1245.
28. Meny G.M., Santos-Zabala L., Szallasi A., Stramer S.L. West Nile virus infection transmitted by granulocyte transfusion. Blood 2011, 117:5778-5779.
29. Thompson N.D., Perz J.F., Moorman A.C., Holmberg S.D. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. Ann Intern Med 2009, 150:33-39.
30. Delarocque-Astagneau E., Pillonel J., De Valk H., Perra A., Laperche S., Desenclos J.C. An incident case-control study of modes of hepatitis C virus transmission in France. Ann Epidemiol 2007, 17:755-762.
31. Acute hepatitis C virus infections attributed to unsafe injection practices at an endoscopy clinic-Nevada, 2007. MMWR 2008, 57:513-517. Centers for Disease Control and Prevention (CDC).
32. Fischer G.E., Schaefer M.K., Labus B.J., Sands L., Rowley P., Azzam I.A., et al. Hepatitis C Virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007-2008. Clin Infect Dis 2010, 51:267-273.
33. Epstein J.S., Holmberg J.A. Progress in monitoring blood safety. Transfusion 2010, 50:1408-1412.
34. Zou S., Fang C.T., Dodd R.Y. A method for estimating incidence rate of infectious diseases among first-time blood donors. Transfusion 2008, 48:1827-1832.
35. Zou S., Dodd R.Y., Stramer S.L., Strong D.M. Likelihood of infectivity for hepatitis B, C and retroviruses among tissue donors in the United States. N Engl J Med 2004, 351:751-759. for the Tissue Safety Study Group.
36. Whitaker B.I., Green J., King M.R., Leibeg L.L., Mathew S.M., Schlumpf K.S., et al. The 2007 National blood collection and utilization survey report. The United States Department of Health and Human Services http://www.hhs.gov/ophs/bloodsafety/2007nbcus_survey.pdf.
37. Anderson S.A., Yang H., Gallagher L.M., O'Callaghan S., Forshee R.A., Busch M.P., et al. Quantitative estimate of the risks and benefits of possible alternative blood donor deferral strategies for men who have had sex with men. Transfusion 2009, 49:1102-1114.
38. Busch M.P. Closing the windows on viral transmission by blood transfusion. Blood safety in the new millennium. AABB 2000 Emily Cooley Seminar Book 2001, 33-54. American Association of Blood Banks, Bethesda. S.L. Stramer (Ed.).
39. Stramer S.L. Pooled hepatitis B virus DNA testing by nucleic acid amplification: implementation or not. Transfusion 2005, 45:1242-1246.
40. Vamvakas E.C. Uses and sources of data on long-term survival after blood transfusion. Transfus Med Rev 2003, 17:194-208.
41. Dorsey K., Zou S., Schonberger L.B., Sullivan M., Kessler D., Notari E., et al. Lack of evidence of transfusion transmission of Creutzfeldt-Jakob disease in a US surveillance study. Transfusion 2009, 49:977-984.
42. Stramer S.L., Chambers L., Page P.L., Wagner A.G., Gibble J. Third reported US case of breakthrough HIV transmission from NAT screened blood. Transfusion 2003, 43(9S):40A-41A. (Abstract).
43. Stramer S.L., Eder A.F., Foster G.A., Dy B.A., Krysztof D., Trouen-Trend J., et al. Investigation of reported cases of suspected transfusion transmission of HIV by the American Red Cross. Transfusion 2009, 49(3S):4A. (Abstract).
44. Kleinman S.H., Lelie N., Busch M.P. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009, 49:2454-2489.
45. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341:556-562.
46. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., Alter M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
47. McQuillan G.M., Kruszon-Moran D., Denniston M.M., Hirsch R. Viral hepatitis. NCHS Data Brief 2010, 27:1-8.
48. Zou S., Notari E.P., Stramer S.L., Wahab F., Musavi F., Dodd R.Y. Patterns of age- and gender-specific prevalence of major bloodborne infections in US blood donors, 1995-2002-American Red Cross blood donor study. Transfusion 2004, 44:1640-1647. for the ARCNET Study Group.
49. Zou S., Eder A.F., Musavi F., Notari E.P., Fang C.T., Dodd R.Y. Implementation of the uniform donor history questionnaire across the American Red Cross Blood Services: increased deferral among repeat presenters but no measurable impact on blood safety. Transfusion 2007, 47:1990-1998. for the ARCNET Study Group.
50. Glynn S.A., Smith J.W., Schreiber G.B., Kleinman S.H., Nass C.C., Bethel J., et al. Retrovirus Epidemiology Donor Study. Repeat whole-blood and plateletpheresis donors: unreported deferrable risks, reactive screening tests, and response to incentive programs. Transfusion 2001, 41:736-743.
51. Orton S.L., Stramer S.L., Dodd R.Y., Alter M.J. Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV. Transfusion 2004, 44:275-281.
52. Zou S., Notari E.P., Musavi F., Dodd R.Y. Current impact of the confidential unit exclusion option. Transfusion 2004, 44:651-657. for the ARCNET Study Group.
53. O'Brien S.F., Fan W., Ram S.S., Goldman M., Nair R.C., Chiavetta J.A., Vamvakas E.C. Face-to-face interviewing in predonation screening: lack of effect on detected human immunodeficiency virus and hepatitis C virus infections. Transfusion 2006, 46:1380-1387.
54. Zou S., Musavi F., Notari E.P., Rios J.A., Trouern-Trend J., Fang C.T. Donor deferral and resulting donor loss at the American Red Cross Blood Services, 2001-2006. Transfusion 2008, 48:2531-2539.
55. Custer B. The cost of blood: did you pay too much or did you get a good deal?. Transfusion 2010, 50:742-744.
56. Stramer S.L., Hollinger F.B., Katz L.M., Kleinman S., Metzel P.S., Gregory K.R., Dodd R.Y. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009, 49(Suppl 2):1S-29S.
57. Mohammed H., Linnen J.M., Muñoz-Jordán J.L., Tomashek K., Foster G., Broulik A.S., et al. Dengue virus in blood donations, Puerto Rico, 2005. Transfusion 2008, 48:1348-1354.
58. Johnson S.T., Cable R.G., Tonnetti L., Spencer B., Rios J., Leiby D.A. Seroprevalence of Babesia microti in blood donors from Babesia-endemic areas of the northeastern United States: 2000 through 2007. Transfusion 2009, 49:2574-2582.
59. Leiby D.A., Gill J.E. Transfusion-transmitted tick-borne infections: a cornucopia of threats. Transfus Med Rev 2004, 18:293-306.
60. Orton S.L., Stramer S.L., Dodd R.Y. Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors. Transfusion 2006, 46:272-277.
61. Zou S., Foster G.A., Dodd R.Y., Petersen L.R., Stramer S.L. West Nile fever characteristics among viremic persons identified through blood donor screening. JID 2010, 202:1354-1361.
62. Centers for Disease Control and Prevention. Advancing HIV Prevention: New Strategies for a Changing Epidemic. http://www.cdc.gov/hiv/aboutDHAP.htm.
63. Purcell D.W., McCree D.H. Recommendations from a research consultation to address intervention strategies for HIV/AIDS prevention focused on African Americans. Am J Public Health 2009, 99:1937-1940.